Cachet Pharmaceutical Co., Ltd. (SHE:002462)
China · Delayed Price · Currency is CNY 15.66
+0.05 (0.32%)
Feb 27, 2026, 3:04 PM CST
Cachet Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 19,953 | 23,985 | 29,923 | 26,220 | 25,626 | 23,256 |
Other Revenue | 33.96 | 33.96 | 73.25 | - | - | - |
| 19,987 | 24,019 | 29,996 | 26,220 | 25,626 | 23,256 | |
Revenue Growth (YoY) | -25.14% | -19.93% | 14.40% | 2.32% | 10.19% | 4.82% |
Cost of Revenue | 18,653 | 22,431 | 28,077 | 24,116 | 23,493 | 21,178 |
Gross Profit | 1,334 | 1,588 | 1,919 | 2,104 | 2,133 | 2,078 |
Selling, General & Admin | 702.13 | 882.78 | 1,052 | 1,153 | 1,088 | 915.23 |
Other Operating Expenses | 55.8 | 48.43 | 50.63 | 45.8 | 44.73 | 40.27 |
Operating Expenses | 921.48 | 1,026 | 1,186 | 1,273 | 1,159 | 997.23 |
Operating Income | 412.37 | 561.8 | 733.78 | 831 | 973.49 | 1,081 |
Interest Expense | -99.04 | -129.18 | -166.35 | -188.57 | -164.24 | -180.8 |
Interest & Investment Income | 19.9 | 19.48 | 31.12 | 22.43 | 18.66 | 20.16 |
Currency Exchange Gain (Loss) | -0.21 | -0.21 | 0.57 | 0.18 | -0.66 | -0.37 |
Other Non Operating Income (Expenses) | -23.16 | -27.14 | -30.13 | -30.96 | -12.17 | -32.26 |
EBT Excluding Unusual Items | 309.86 | 424.74 | 568.99 | 634.08 | 815.08 | 887.48 |
Impairment of Goodwill | -80.41 | -80.41 | -40.05 | -20.21 | -13.71 | -76.29 |
Gain (Loss) on Sale of Investments | -0 | 0.04 | -3.5 | -2.63 | -0.52 | -9.79 |
Gain (Loss) on Sale of Assets | 59.16 | 201.43 | 0.85 | 1.67 | 0.74 | 1.28 |
Asset Writedown | -16.2 | -6.14 | -0.3 | -1.88 | -0.21 | -0.15 |
Other Unusual Items | 40.72 | 12.01 | 29.29 | 33.88 | 22.59 | 11.78 |
Pretax Income | 313.12 | 551.66 | 555.28 | 644.91 | 823.98 | 814.31 |
Income Tax Expense | 160.79 | 229.99 | 178.75 | 176.59 | 222.1 | 223.4 |
Earnings From Continuing Operations | 152.33 | 321.67 | 376.53 | 468.31 | 601.88 | 590.9 |
Minority Interest in Earnings | -81.3 | -161.01 | -126.47 | -171.38 | -248 | -273.32 |
Net Income | 71.03 | 160.67 | 250.06 | 296.94 | 353.88 | 317.59 |
Net Income to Common | 71.03 | 160.67 | 250.06 | 296.94 | 353.88 | 317.59 |
Net Income Growth | -70.91% | -35.75% | -15.79% | -16.09% | 11.43% | -15.53% |
Shares Outstanding (Basic) | 294 | 292 | 291 | 291 | 292 | 291 |
Shares Outstanding (Diluted) | 294 | 292 | 291 | 291 | 292 | 291 |
Shares Change (YoY) | 1.01% | 0.47% | -0.12% | -0.46% | 0.38% | 11.60% |
EPS (Basic) | 0.24 | 0.55 | 0.86 | 1.02 | 1.21 | 1.09 |
EPS (Diluted) | 0.24 | 0.55 | 0.86 | 1.02 | 1.21 | 1.09 |
EPS Growth | -71.20% | -36.05% | -15.69% | -15.70% | 11.01% | -24.31% |
Free Cash Flow | 918.04 | 164.93 | 1,396 | -351.98 | 666.17 | 856.88 |
Free Cash Flow Per Share | 3.13 | 0.56 | 4.80 | -1.21 | 2.28 | 2.94 |
Dividend Per Share | 0.170 | 0.170 | 0.260 | 0.310 | 0.370 | 0.330 |
Dividend Growth | -34.62% | -34.62% | -16.13% | -16.22% | 12.12% | -17.50% |
Gross Margin | 6.67% | 6.61% | 6.40% | 8.03% | 8.32% | 8.94% |
Operating Margin | 2.06% | 2.34% | 2.45% | 3.17% | 3.80% | 4.65% |
Profit Margin | 0.36% | 0.67% | 0.83% | 1.13% | 1.38% | 1.37% |
Free Cash Flow Margin | 4.59% | 0.69% | 4.65% | -1.34% | 2.60% | 3.69% |
EBITDA | 402.21 | 613.16 | 867.17 | 989.04 | 1,114 | 1,208 |
EBITDA Margin | 2.01% | 2.55% | 2.89% | 3.77% | 4.35% | 5.19% |
D&A For EBITDA | -10.16 | 51.36 | 133.39 | 158.03 | 140.26 | 127.12 |
EBIT | 412.37 | 561.8 | 733.78 | 831 | 973.49 | 1,081 |
EBIT Margin | 2.06% | 2.34% | 2.45% | 3.17% | 3.80% | 4.65% |
Effective Tax Rate | 51.35% | 41.69% | 32.19% | 27.38% | 26.96% | 27.43% |
Revenue as Reported | 19,987 | 24,019 | 29,996 | 26,220 | 25,626 | 23,256 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.